Literature DB >> 26781226

Expanding the clinicopathological spectrum of late cutaneous Lyme borreliosis (acrodermatitis chronica atrophicans [ACA]): A prospective study of 20 culture- and/or polymerase chain reaction (PCR)-documented cases.

Cédric Lenormand1, Benoît Jaulhac2, Sébastien Debarbieux3, Nicolas Dupin4, Florence Granel-Brocard5, Henri Adamski6, Cathy Barthel2, Bernard Cribier1, Dan Lipsker7.   

Abstract

BACKGROUND: The diagnosis of acrodermatitis chronica atrophicans (ACA), the late cutaneous manifestation of Lyme borreliosis, can be challenging. Histologic changes in ACA have been described in a few studies from endemic countries, relying on cases documented by serology only.
OBJECTIVES: We sought to reassess the clinicopathological spectrum of ACA in a series of thoroughly documented cases.
METHODS: Patients prospectively included in a national prospective study were selected on the basis of positive culture and/or polymerase chain reaction of a skin biopsy sample. The diagnosis of ACA was confirmed by reviewing the clinical and serologic data. Histopathological samples were carefully reviewed.
RESULTS: Twenty patients were included. Unusual clinical features (ie, numerous small violaceous patches and equidistant small spinous papules with background faint erythema) were observed in 2 patients. Histopathological examination revealed a classic plasma cell-rich perivascular and interstitial pattern with telangiectases in 16 of 25 samples, whereas strikingly prominent granuloma annulare-like or lichenoid features were observed in 4 and 2 of 25 cases, respectively, and discrete nonspecific minor changes in 3 of 25 cases. LIMITATIONS: The small number of patients was a limitation.
CONCLUSIONS: Genuine culture- and/or polymerase chain reaction-proven ACA can rarely present as numerous violaceous patches or cluster of spinous papules clinically, and as a granuloma annulare-like or lichenoid dermatosis histologically.
Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Borrelia burgdorferi; acrodermatitis chronica atrophicans; borreliosis; granuloma annulare; lichenoid dermatitis; plasma cells

Mesh:

Substances:

Year:  2016        PMID: 26781226     DOI: 10.1016/j.jaad.2015.10.046

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

Review 1.  Clinical spectrum of Lyme disease.

Authors:  Jesus Alberto Cardenas-de la Garza; Estephania De la Cruz-Valadez; Jorge Ocampo-Candiani; Oliverio Welsh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-19       Impact factor: 3.267

2.  Acrodermatitis chronica atrophicans: clinical and microbiological characteristics of a cohort of 693 Slovenian patients.

Authors:  K Ogrinc; V Maraspin; L Lusa; T Cerar Kišek; E Ružić-Sabljić; F Strle
Journal:  J Intern Med       Date:  2021-03-13       Impact factor: 13.068

3.  Better drugs for Lyme disease: focus on the spirochete.

Authors:  Raphael B Stricker; Marianne J Middelveen
Journal:  Infect Drug Resist       Date:  2018-09-07       Impact factor: 4.003

4.  Multilocus sequence typing of clinical Borreliella afzelii strains: population structure and differential ability to disseminate in humans.

Authors:  Floriane Gallais; Sylvie J De Martino; Erik A Sauleau; Yves Hansmann; Dan Lipsker; Cédric Lenormand; Emilie Talagrand-Reboul; Pierre H Boyer; Nathalie Boulanger; Benoît Jaulhac; Frédéric Schramm
Journal:  Parasit Vectors       Date:  2018-06-28       Impact factor: 3.876

Review 5.  Immunoserological Diagnosis of Human Borrelioses: Current Knowledge and Perspectives.

Authors:  Emilie Talagrand-Reboul; Alice Raffetin; Pierre Zachary; Benoît Jaulhac; Carole Eldin
Journal:  Front Cell Infect Microbiol       Date:  2020-05-19       Impact factor: 5.293

6.  Case Report: Borrelia-DNA Revealed the Cause of Arthritis and Dermatitis During Treatment With Rituximab.

Authors:  Johanna Sjöwall; Georgios Xirotagaros; Chris D Anderson; Christopher Sjöwall; Charlotte Dahle
Journal:  Front Neurol       Date:  2021-02-12       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.